This Low B12 Cardiovascular Risk Review explains how vitamin B12, homocysteine and cardiovascular disease may connect, what research shows, what it cannot show, and what to do next.
Reviewed against current clinical guidance
Low B12 can increase homocysteine, a marker associated with vascular stress.
Supplements correct deficiency. They do not automatically prevent heart attacks.
01 · What the research says
A low B12 level is a treatable finding, not a diagnosis of cardiovascular disease. This Low B12 Cardiovascular Risk Review separates association from causation and summarizes where the evidence stands today.
European Journal of Preventive Cardiology
Lower B12 status tracked with higher cardiovascular risk, but the association weakened after accounting for kidney function and inflammation.
View study noteThe Lancet Neurology
B12, folate and B6 lowered homocysteine. Clinical benefit was clearest when kidney function was considered and B12 deficiency was corrected.
View study noteDiabetes Care
Long-term metformin use was linked to lower B12. Monitoring and replacing B12 is recommended; cardiovascular prevention was not the trial’s primary endpoint.
View study note02 · The biology
B12 helps your body process homocysteine. When B12 is low, homocysteine can accumulate—but that is only one piece of cardiovascular health.
Diet, absorption, medicines and age can all play a role.
B12 is one of the nutrients needed to recycle it.
Blood pressure, smoking and cholesterol matter more.
03 · Your next step
This is not a diagnosis. It’s a quick way to spot reasons to ask a clinician about testing.
04 · Supplement guide
A blood test can clarify whether you need B12 and whether a second marker is useful.
Oral B12 works for many people. Injections may be recommended when absorption is impaired.
Review diet, medicines and gut health with a qualified clinician.
05 · Blog
These blog posts target keyword clusters such as metformin vitamin B12 deficiency cardiovascular risk, low B12 and stroke risk review, and who should test vitamin B12 for CV risk.
Low vitamin B12 often appears in cardiovascular conversations, but the strongest conclusion is still careful risk interpretation rather than automatic causation.
The biological case is strongest in the homocysteine pathway: low B12 can impair one-carbon metabolism, and hyperhomocysteinemia can injure vascular endothelium.
B12 supplements clearly treat deficiency. The harder question is whether homocysteine lowering changes hard cardiovascular outcomes in routine practice.